System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish 5 citations

PubMed: 36212403 DOI: 10.3389/fonc.2022.952640

Impact of genetic polymorphisms of drug transporters and and regulators of xenobiotic transport and metabolism and on clinical efficacy of dasatinib in chronic myeloid leukemia.

Front Oncol 12:952640

Authors: Anna Marta Madejczyk, Federico Canzian, Joanna Góra-Tybor, Daniele Campa, Tomasz Sacha, Dorota Link-Lenczowska, Izabela Florek, Witold Prejzner, M Całbecka, M Rymko, M Dudziński, Magdalena Julita Orzechowska, Krzysztof Jamroziak

Affiliations

  • Department of Hematology, Medical University of Łódź, Łódź, Poland.
  • Genomic Epidemiology Group, German Cancer Research Center Deutsche Krebsforschungszentrum (DKFZ), Heidelberg, Germany.
  • Department of Biology, University of Pisa, Pisa, Italy.
  • Department of Hematology, Jagiellonian University Medical College, Kraków, Poland.
  • Department of Hematology, Medical University of Gdańsk, Gdańsk, Poland.
  • Department of Hematology, Copernicus Specialist Municipal Hospital, Toruń, Poland.
  • Department of Hematology, Teaching Hospital No 1, Rzeszów, Poland.
  • Department of Molecular Carcinogenesis, Chair of Molecular Medicine and Biotechnology, Faculty of Medicine, Medical University of Łódź, Łódź, Poland.
  • Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.

Abstract

Introduction

Functional single-nucleotide polymorphisms (SNPs) in genes regulating cellular uptake, elimination, and metabolism of xenobiotics may potentially influence the outcome of chronic myeloid leukemia (CML) patients treated with BCR-ABL1 tyrosine kinase inhibitors (TKI). Dasatinib, a second-generation TKI, is a substrate of the ABC-superfamily xenobiotic transporters ABCB1 (MDR1, Pg-P) and ABCG2 (BCRP). Pregnane X receptor (PXR, NR1I2) and constitutive androstane receptor (CAR, NR1I3) are involved in the control of expression of and

Aim of the study

In this study, we assessed the impact of inherited variants in , , , and genes on dasatinib efficacy and toxicity in CML.

Materials and methods

Sixty-one tagging SNPs in , , , and genes were analyzed by real-time quantitative PCR with specific probes in 86 CML patients who failed imatinib therapy.

Results

We found the associations between SNPs rs7787082 (, OR = 0.2; 95% CI = 0.06-0.66, p = 0.008), rs12505410 (, OR = 3.82; 95% CI = 1.38-10.55; p = 0.010), and rs3114018 (, OR = 0.24; 95% CI = 0.08-0.71; p = 0.010) and the probability of achieving CCyR. Furthermore, progression-free survival (PFS) was significantly influenced by SNPs rs3732357 (HR = 0.2, 95% CI = 0.26-0.70; p = 0.001), rs3732360 (HR = 0.59; 95% CI = 0.38-0.93; p = 0.020), rs11917714 (HR = 0.58; 95% CI = 0.36-0.92; p = 0.020), and rs3732359 (HR = 0.57; 95% CI = 0.36-0.91; p = 0.024) in ; rs2307418 (HR = 2.02; 95% CI = 1.19-3.43; p = 0.048) in ; and rs2235023 (HR = 2.49; 95% CI = 1.13-5.50; p = 0.011) and rs22114102 (HR = 1.90; 95% CI = 1.00-3.63; p = 0.028) in . Moreover, overall survival (OS) was impacted by rs3842 (HR = 1.84; 95% CI = 1.01-3.33; p = 0.012) and rs2235023 (HR = 2.28; 95% CI = 1.03 = 5.02; p = 0.027) in , rs11265571 (HR = 1.59; 95% CI = 0.82-3.08; p = 0.037) and rs2307418 (HR = 73.68; 95% CI = 4.47-1215.31; p = 0.003) in , and rs3732360 (HR = 0.64; 95% CI = 0.40 = 1.04; p = 0.049) in . Taking into account the influence of the tested SNPs on treatment toxicity, we found a significant relationship between allele G of polymorphism in the rs7787082 (OR = 4.46; 95% CI = 1.38-14.39 p = 0.012) and hematological complications assuming the codominant gene inheritance model as well as a significant correlation between the presence of minor allele (G) of SNP rs2725256 in the gene (OR = 4.71; 95% CI = 1.20-18.47; p = 0.026) and the occurrence of non-hematological complications assuming a recessive gene inheritance model.

Conclusion

Our data suggest that inherited variants in the genes encoding for proteins involved in the transport of xenobiotics may modify the toxicity and efficacy of dasatinib therapy in CML patients.

MeSH

Leukemia, Myelogenous, Chronic, Bcr-Abl Positive, Pharmaceutical Preparations, Therapeutics, Leukemia, Myeloid, Genes, Polymorphism, Genetic, Disease-Free Survival, Xenobiotics, Polymorphism, Single Nucleotide, Alleles, Dasatinib, Pregnane X Receptor, Progression-Free Survival

Cited by